Cloudera, Inc., the leading provider of the modern platform for machine learning and advanced analytics built on the latest open source technologies, announced that Inova Translational Medicine Institute (ITMI), a global leading medical research institute, has deployed Cloudera Enterprise to securely analyse massive collections of clinical and genomic data at unprecedented speeds and scale for faster innovations in translational medicine research.
As part of the Inova Center for Personalized Health (ICPH), ITMI’s team of leading scientists, researchers, analysts and collaborators use machine learning algorithms on terabytes of clinical and genomic information to identify the genetic links to diseases. They make discoveries from the data insights and, in collaboration with the treating physician, develop personalized treatment plans for patients. This approach is also known as precision medicine and has the power to help patients live longer, healthier lives.
Genetics plays a role in the majority of leading causes of death in the United States, including heart disease, cancer and diabetes. The Institute collects clinical data from thousands of Inova patients born from over 110 countries. Just one person’s unique DNA contains six billion bits of information. Mapping individual’s DNA codes into genome sequences helps scientists determine the cause of diseases and discover transformative treatments. As part of this process, ITMI is also assembling what is expected to be one of the world’s largest whole genome sequence databases connected to patient information in a healthcare system.
“The challenge for ITMI researchers and scientists was to analyse our highly complex, massive collection of raw data faster and more efficiently and translate insights into practical patient care. We’re now able to get answers in minutes and seconds and can find correlations that we couldn’t see before,” said Aaron Black, chief data officer of ITMI. “Our researchers used to spend 80 percent of their time on data wrangling and only a sliver of time on the analytics. We’re in the process of reversing that. We can now accelerate the pace of genomic discovery and dramatically change the way we interact with our research teams. We believe that will improve our ability to provide the right treatments to the right patients and ultimately, improve outcomes. What Cloudera has done is made this imminently possible.”